Pfizer’s Weight Management Drug Wins China Approval

2026-03-12 20:49:56

Pfizer’s GLP-1 treatment, Xianweiying (ecnoglutide), has received approval in China for long-term weight management in overweight or obese adults. This move by Pfizer significantly bolsters its position in the rapidly expanding weight-loss drug market, introducing new competition. The drug is administered as a once-weekly injection and was previously approved in China for Type 2 diabetes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.